44results about "Immunoglobulins" patented technology

Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.

The present invention relates to chromatography ligands having improved caustic stability, e.g., ligands based on immunoglobulin-binding proteins such as, Staphylococcal protein A, as well as methods of making and using such ligands.

Specially designed non-mammalian GnRH, its analogs, or biometics resistant to degradation by peptidase, are disclosed. The GnRH analogs are further defined as analogs of GnRH II or salmon GnRH. These non-mammalian analogs incorporate D-arginine, D-leucine, D-tBu-Serine, D-Trp or other active D amino acids at position 6 and ethylamide, aza-Gly-amide or other Gly amide at position 10. The D-Arg (6)—GnRH II-ethylamide, D-Arg (6)—GnRH II-aza-Gly (10)-amide, the D-Arg (6)—salmon GnRH ethylamide, and D-Arg (6)—salmon GnRH-aza-Gly (10)-amide analogs are also provided, and demonstrate preferential binding to immune system non-mammalian GnRH receptors. These non-mammalian GnRH or its analogs, or long-acting preparation, biometics or their antibodies may be used in pharmaceutical preparation, and specifically in treatment of various immune system disorders. The non-mammalian GnRH or its analogs are also provided in pharmaceutical preparations that may be used clinically for treating immune system disorders when used in very low doses and administered in pulsatile fashion. The aza-Gly (10) amide non-mammalian analogs are yet other embodiments of the non-mammalian GnRH or its analogs provided as a part of the invention. The use of agents that regulate the production or antibodies or In addition, the detection of non-mammalian GnRH or GnRH II or the non-mammalian GnRH receptors may be used as a diagnostic tool.

The present invention provides methods of treating, preventing or ameliorating the symptoms of Latent Autoimmune Diabetes in Adults (LADA) and adult-onset type 1 diabetes through the use of anti-human CD3 antibodies. In particular, in invention provides methods of preventing or delaying insulin requirement in patients diagnosed with LADA. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor / alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-human CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies.

The present invention provides means to modify the tropism of recombinant adenoviral vectors using genetic methods to alter the adenoviral fiber cell-binding protein. The present invention generates an adenovirus with modified fiber gene such that novel tropism is achieved. This recombinant adenovirus has a fiber gene modified in the HI loop domain.

This invention provides compounds of general formula (T): (I) wherein A, B, R1, R2, and X are as defined in this specification, and pharmaceutical compositions prepared from the same, for use in treatment of hepatitis C virus and / or human immunodeficiency virus.

The present invention provides pegylated hemoglobins comprising a maleimide polyethylene glycol (PEG) conjugated to a thiol moiety of a cysteine residue of hemoglobin, methods of preparing the pegylated hemoglobins, compositions and blood substitutes comprising the pegylated hemoglobins, and methods of treating a subject which comprise administering to the subject blood substitutes comprising vasoinactive pegylated hemoglobins.

The invention relates to an ANGPTL4 polypeptide for use in the preservation of vascular endothelial cell barrier integrity and reduction in no-reflow phenomenon with myocardial infarction.